Studies how hormone therapy affects PSMA in men with metastatic prostate cancer
Tests hormone therapy in men with untreated metastatic prostate cancer.
Plain-language title generated from the registry record
Registry title: The effect of androgen deprivation therapy on the expression of prostate
specific membrane antigen (PSMA) in treatment naive metastatic prostate
cancer
Key facts
- Where
- Turku, FinlandSee the site
- Phase
- Phase 2
Where in Finland
- Turku University HospitalTurku, FinlandTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Turku University Hospital
- Trial code
- NCT03876912EU 2024-519516-14-01
- Record updated
- 28 January 2025
- Original description
To demonstrate that PSMA-flare seen 2-3weeks after initiation of ADT at baseline is more common in bony lesions than in prostatic lesionsRead full original descriptionShow less
The effect of androgen deprivation therapy on the expression of prostate specific membrane antigen (PSMA) in treatment naive metastatic prostate cancer
To demonstrate that PSMA-flare seen 2-3weeks after initiation of ADT at baseline is more common in bony lesions than in prostatic lesions
Inclusion: Age: 40 to 85 years old; Language spoken: Finnish and Swedish; Diagnosis: Histologically confirmed adenocarcinoma of prostate; Adequate histological sampling consisting of at least 3 biopsy samples from each lobe; No previous surgical, radiation or endocrine treatment for prostate carcinoma; Clinical stage: T1c-T4NanyM1; Serum creatinine ≤ 1,5 x ULN; Mental status: Patients must be able to understand the meaning of the study; Informed consent: The patient must sign the appropriate Ethical Committee approved informed consent documents in the presence of the designated staff.
Exclusion: Previous PC treatment; Uncontrolled serious infection.